FDA policy in response to COVID-19 offers blueprint for regulation of LDTs: study

FDA's temporary changes to laboratory-developed test regulation early in the pandemic can provide a blueprint for ongoing regulatory oversight of the field, a study by researchers at Massachusetts General Hospital (MGH) has found.

FDA policy in response to COVID-19 offers blueprint for regulation of LDTs: study